Radiofrequency Neurolysis of the Posterior Nasal Nerve: A Systematic Review and Meta‐Analysis
Eyad Jamileh, Fahad Muhammad, Mohamed Xamza, Khadijah Ahmed, Abdullah Ahmed, Munir AhmedABSTRACT
Objectives
Temperature‐controlled radiofrequency (TCRF) neurolysis of the posterior nasal nerve is a minimally invasive treatment for chronic rhinitis. While early studies show short‐term efficacy, long‐term durability remains unclear. This study evaluated the short‐ and long‐term efficacy and safety of TCRF neurolysis across discrete follow‐up intervals.
Data Sources
PubMed/MEDLINE, Embase, and the Cochrane Library were searched from inception to March 2026.
Review Methods
Following PRISMA 2020 guidelines (PROSPERO: CRD420261345320), studies evaluating adults undergoing TCRF neurolysis for chronic rhinitis with quantitative outcomes were included. Random‐effects meta‐analyses pooled outcomes at 3 months, 6 months, 12 months, 2 years, and 3 years.
Results
Twelve studies (924 patients) were included. TCRF neurolysis significantly reduced total nasal symptom scores (rTNSS) across all intervals: 3 months (−3.96, 95% CI −4.26 to −3.67), 6 months (−4.50, 95% CI −4.91 to −4.09), 12 months (−4.70, 95% CI −5.04 to −4.37), 2 years (−5.06, 95% CI −5.67 to −4.44), and 3 years (−4.59, 95% CI −5.00 to −4.19). Symptom responder rates (≥ 30% improvement) rose from 74% at 3 months to 81%–84% during long‐term follow‐up. Mini Rhinoconjunctivitis Quality of Life Questionnaire scores demonstrated sustained improvements up to 3 years. Adverse events were infrequent, minor, and transient.
Conclusion
TCRF neurolysis provides safe, clinically meaningful, and durable improvements in nasal symptoms and quality of life for up to 3 years, offering a robust therapeutic option for medically refractory chronic rhinitis.
Level of Evidence
1.